X
<

How Zimmer Biomet's Transition Looks for 2017

PART:
1 2 3 4 5 6
Part 3
How Zimmer Biomet's Transition Looks for 2017 PART 3 OF 6

Why Zimmer Biomet Made Another Downward Revision to Its Fiscal 2017 Guidance

ZBH’s fiscal 2017 guidance

Zimmer Biomet Holdings (ZBH) announced its 2Q17 earnings results on July 27, 2017, and again made a downward revision to its fiscal 2017 guidance. ZBH reduced its fiscal 2017 guidance during its 1Q17 results announcement on April 27, 2017.

Why Zimmer Biomet Made Another Downward Revision to Its Fiscal 2017 Guidance

Interested in ZBH? Don't miss the next report.

Receive e-mail alerts for new research on ZBH

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

ZBH expects its fiscal 2017 sales to be in the range of $7.8 billion–$7.87 billion. This represents a YoY (year-over-year) growth of ~1.8%–2.7% on a constant currency basis. This estimate also includes a ~1.2% contribution from the LDR Holding acquisition. The previous sales guidance for fiscal 2017 showed sales growth in the range of 3.2%–4.2%.

ZBH’s adjusted diluted EPS (earnings per share) for the full fiscal 2017 is expected to be in the range of $8.2 to $8.3, compares with the previous guidance range of $8.5 to $8.6. Investors can participate in Zimmer Biomet’s growth potential by investing in the Vanguard S&P 500 ETF (VOO), which has ~0.11% of its total holdings in VBH.

3Q17 guidance

For 3Q17, ZBH sales are estimated to be in the range of $1.82 billion–$1.85 billion. Currency headwinds are expected to impact the company’s sales by ~0.5%, with constant currency YoY sales growth in the range of -0.5% to 1%.

ZBH’s 3Q17 revenue estimate includes the contribution of ~30 basis points from the LDR acquisition. Fewer billing days in the quarter as compared with last year are expected to impact sales by -130 basis points.

By comparison, competitors Stryker (SYK), Baxter (BAX), and Abbott Laboratories (ABT) are expected to register fiscal 2017 revenue growth of ~8.5%, 3.2%, and 26.9%, respectively.

X

Please select a profession that best describes you: